USPTO serial 97542504
CSL SEQIRUS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 5, 2025
- Examiner
- CAYSIDO, REBECCA TOLENTINO
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with CSL SEQIRUS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Maidenhead, Berkshire, GB
Maidenhead, Berkshire, GB
Maidenhead, Berkshire, GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Nancy Sabarra
Nancy Sabarra FROSS ZELNICK LEHRMAN & ZISSU, P.C.151 WEST 42ND ST., 17TH FL.NEW YORK, NY 10036United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical and biological reagents for scientific purposes, research purposes, and non-medical purposes; cell culture reagents and media for scientific and research use; laboratory and scientific test kits for laboratory or research use, namely, reagent kits comprising generic DNA circle, DNA primers, polymerase and buffers for use in biotechnology fields; chemical preparations for scientific and industrial purposes; diagnostic and testing agents, namely, diagnostic reagents and diagnostic testing preparations for scientific and research use; chemical and biological reagents for non-medical purposes; chemical and biological reagents for industrial use for antibody screening, blood grouping, and for the typing and detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes all for non-medical purposes; chemical test kits for the detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes for laboratory or research use; chemical preparations for industrial use for anti-body screening, blood grouping, and the typing and detection of specific blood cells | ACTIVE | — |
| 005 | Pharmaceutical preparations and substances for the treatment and prevention of influenza, respiratory disease and disorders, infectious diseases and disorders, cardiovascular diseases and disorders, stroke, and heart failure; pharmaceutical preparations and substances, namely, anti-virals and antibiotics; vaccines; blood products, namely, blood for medical purposes, blood plasma and cord blood for medical purposes; serums, namely, anti-venoms; medicated serums for the treatment of blood disorders and bleeding disorders; antibodies for use in the treatment of infectious diseases, cancer and autoimmune diseases; monoclonal and polyclonal antibodies for medical purposes; therapeutic monoclonal and polyclonal antibodies and antibodies for use in the treatment of infectious diseases; influenza vaccines; adjuvants for medical purposes and antigens being protein arrays for medical purposes; pharmaceutical preparations and substances for the treatment and prevention of blood or bleeding disorders; blood products, namely, blood plasma, reagent blood cells for medical use; products derived from blood and products derived from recombinant DNA technology, namely, blood substitutes being immunoglobulins, human albumin, blood clotting factors, plasma volume expanders, blood proteins for therapeutic human use; test kits, namely, invitro diagnostic reagent test kits comprised of medical diagnostic reagents for use in detecting cell mediated immune response; pharmaceutical preparations and substances, namely, RhD reagents for medical use for the detection of specific antigens and in blood typing; pharmaceutical preparations, namely, reagent red blood cells for medical purposes used to detect antibodies or IgG subtypes; pharmaceutical preparations, namely, monoclonal and polyclonal antibodies for pharmaceutical use; pharmaceutical preparations, namely, reagents for medical and clinical use for the typing and detection of specific blood cells, and the detection of relevant compliment components and immunoglobulin subtypes; diagnostic agents for medical purposes | ACTIVE | — |
| 041 | Education services including medical education services, namely, conducting classes, seminars, conferences, and workshops in the fields of pharmaceuticals, vaccines, biotechnology, biotherapy, immunology, rare diseases and blood conditions; health education, namely, providing classes in the field of health, vaccines, and immunology; consultancy services relating to education; provision of education services, namely, arranging and conducting of online conferences and symposia in the field of medical science via an online forum; provision of medical training and education courses in the field of health and medicine; publication of electronic educational materials; dissemination of printed and electronic educational material of others in the field of health and medicine; weblog services, namely, providing online non-downloadable blogs in the field of health and medicine; electronic publication of information on a wide range of topics, including online and over a global computer network, namely, electronic publishing of electronic publications featuring information on a wide range of topics | ACTIVE | — |
| 042 | Scientific and technological services, namely, scientific research and product development in the field of vaccines; scientific research, analysis, and testing in the field of medicine, pharmaceuticals, vaccines, and biotechnology; research and development services, namely, scientific, medical, pharmaceutical and blood products research and development services; industrial analysis of biotechnology and immunology processes for product development in the field of pharmaceuticals and vaccines; providing medical research and scientific research information about the results of clinical trials for pharmaceuticals and vaccines; providing medical research and scientific research information in the field of clinical trials; provision of testing facilities for pharmaceutical research; laboratory analysis and research in the fields of pharmaceuticals, vaccines, bacteriology, and chemistry; management of scientific research projects; providing technical research in the field of pharmaceutical studies through preparation of technical studies, technical reports, scientific reports; providing technical research in the field of pharmaceutical studies through preparation of scientific and medical research projects, preparation of statistics and reports relating to scientific and medical research; provision of scientific research services and facilities, provision of scientific research results, information and outcomes in the field of health and medicine; provision of pharmaceutical research information relating to the aforementioned services; pharmaceutical research advisory and consultancy services relating to the aforementioned services; dissemination of pharmaceutical research and medical research information relating to the aforementioned services over a global computer network; medical laboratory services through scientific testing and screening services, namely, medical laboratory testing of human blood plasma for safety and quality; medical laboratory services regarding human blood plasma | ACTIVE | — |
| 044 | Medical services; medical information services; health care services; health care information services; patient support services, namely, providing an internet-based database of patient medical information where patients can inquire about medical issues and procedures related to vaccination and immunology; providing medical information concerning blood products; providing medical information concerning vaccines, anti-venoms and immunohaematology products being diagnostic reagents; patient support services, namely, providing patient medical information where patients can enquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community via an Internet-based database | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Seqirus UK Limited
- Other trademarks owned by Seqirus UK Limited
- Other trademarks owned by Seqirus UK Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named CSL SEQIRUS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 29, 2026 | PRA7 | REGISTERED - SEC. 7 REQUEST ABANDONED | — |
| Jun 29, 2026 | PRAN | POST REGISTRATION ACTION MAILED NO RESPONSE REQUIRED | — |
| Nov 20, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Nov 17, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Aug 27, 2025 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Aug 5, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 5, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 17, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 17, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 11, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 29, 2025 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| May 27, 2025 | OTHE | CASE RETURNED TO EXAMINATION | — |
| May 27, 2025 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| May 23, 2025 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| May 23, 2025 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| May 19, 2025 | APET | ASSIGNED TO PETITION STAFF | — |
| Apr 16, 2025 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| Mar 25, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 24, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Mar 24, 2025 | EXT2 | SOU EXTENSION 2 FILED | — |
| Mar 24, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 19, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 19, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Sep 19, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Sep 19, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 26, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 30, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 30, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 10, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 28, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 28, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 28, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 28, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 28, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 6, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 5, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 5, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 15, 2023 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Aug 15, 2023 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jun 5, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 5, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 5, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 30, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 30, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 13, 2022 | NWAP | NEW APPLICATION ENTERED | — |